Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study - Concepedia

Concepedia

Publication | Open Access

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study

DOI Full Paper Access

201

Citations

29

References

2013

Year

Franck Morschhauser, Guillaume Cartron, Catherine Thiéblemont, Philippe Solal‐Céligny, Corinne Haïoun, Réda Bouabdallah, Pierre Feugier, Krimo Bouabdallah, Elina Asikanius, Guiyuan Lei,

Journal of Clinical Oncology

Abstract

Obinutuzumab (GA101) 1,600/800 mg achieves early steady-state concentration and clinical activity with an acceptable safety profile in relapsed/refractory DLBCL and MCL, supporting further exploration.

References

	Year	Citations

Page 1